A nurse is planning care for a child who has a prescription for somatropin.
Which of the following interventions should the nurse include to evaluate the therapeutic effect of this medication?
Monitor the child's height monthly.
Verify the child's thyroid function is within the expected reference range.
Check the child's sodium level regularly.
Measure the child's abdominal girth.
The Correct Answer is A
Choice A rationale
Somatropin is a synthetic growth hormone used to treat growth hormone deficiency. The primary therapeutic effect of this medication is to promote linear growth in children. Therefore, monitoring the child's height monthly is a direct and quantifiable measure to evaluate the effectiveness of somatropin therapy and ensure that the child is achieving the expected growth velocity.
Choice B rationale
While thyroid function can influence growth, and growth hormone deficiency can sometimes coexist with or impact thyroid axis, evaluating the therapeutic effect of somatropin directly involves assessing growth. Monitoring thyroid function is important for overall endocrine health but is not the primary measure for the therapeutic effect of somatropin itself, assuming thyroid function is within normal limits (e.g., TSH 0.4-4.0 mIU/L, free T4 0.8-1.8 ng/dL).
Choice C rationale
Checking the child's sodium level regularly is not a direct measure of the therapeutic effect of somatropin. Growth hormone can influence fluid balance, but sodium levels (normal range 135-145 mEq/L) are primarily monitored for hydration status or potential adverse effects like fluid retention, not as an indicator of growth hormone's efficacy in promoting growth.
Choice D rationale
Measuring the child's abdominal girth is a measure of abdominal circumference, primarily used to assess abdominal distention, fluid accumulation, or changes in visceral fat. It is not a relevant parameter for evaluating the therapeutic effect of somatropin, which is specifically aimed at stimulating linear bone growth and overall somatic growth.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is A
Explanation
Choice A rationale
Allopurinol is a xanthine oxidase inhibitor. This enzyme is crucial in the purine catabolism pathway, converting xanthine and hypoxanthine into uric acid. By inhibiting xanthine oxidase, allopurinol effectively decreases the de novo synthesis of uric acid, thereby lowering serum uric acid levels. This reduction prevents the formation of uric acid crystals in joints and tissues, which are responsible for the painful manifestations of gout.
Choice B rationale
Tophus formation is a direct consequence of chronic hyperuricemia, where uric acid crystals accumulate in soft tissues, leading to palpable nodules. Allopurinol's primary mechanism of action is to reduce uric acid levels. By achieving this, it prevents further crystal deposition and can even lead to the regression of existing tophi over time. Therefore, it does not increase tophus formation.
Choice C rationale
Allopurinol's mechanism of action is specifically related to uric acid metabolism. It does not directly influence calcium homeostasis in the body. Calcium levels are primarily regulated by parathyroid hormone, calcitonin, and vitamin D, which are distinct physiological pathways unrelated to xanthine oxidase inhibition. Therefore, it does not lower calcium levels.
Choice D rationale
While allopurinol ultimately helps relieve joint inflammation in gout, it does so indirectly. Its primary action is to reduce uric acid production, which then prevents the formation of inflammatory uric acid crystals. The direct reduction of inflammation is typically achieved by anti-inflammatory drugs like NSAIDs or colchicine, which act on inflammatory mediators or pathways, not directly by allopurinol.
Correct Answer is C
Explanation
Choice A rationale
Metoprolol is a beta-blocker primarily used to treat hypertension, angina, and heart failure. It works by blocking beta-adrenergic receptors, leading to decreased heart rate and blood pressure. It is not indicated for managing tremors or dyskinesias associated with levodopa/carbidopa therapy in Parkinson's disease, as these are typically dopaminergic in origin.
Choice B rationale
Bethanechol is a muscarinic cholinergic agonist that increases bladder tone and stimulates gastrointestinal motility. It is primarily used for urinary retention and gastroesophageal reflux disease. Its mechanism involves directly stimulating muscarinic receptors. It has no role in addressing the motor complications like tremors and twitching seen with levodopa/carbidopa in Parkinson's disease.
Choice C rationale
Amantadine is an antiviral drug also used to treat dyskinesia associated with levodopa therapy in Parkinson's disease. Its precise mechanism of action in Parkinson's is not fully understood, but it is thought to modulate dopaminergic and glutamatergic neurotransmission. It can help reduce tremors, rigidity, and involuntary movements.
Choice D rationale
Gabapentin is an anticonvulsant and neuropathic pain medication. It is structurally related to GABA but does not act directly on GABA receptors. Its mechanism of action involves modulating calcium channels. While it can treat some neurological symptoms, it is not a primary treatment for levodopa-induced tremors and twitching in Parkinson's disease.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.